CPHI Milan, 6–8 October: book your meeting with Canexis Pharma at stand 2D98

Canexis Pharma AG exhibits at CPHI Milan from 6 to 8 October 2026 at stand 2D98 in the Natural Extracts zone. Meetings can be booked in advance via the CPHI Event Planner. On the agenda: specifications and samples of Cannabidiol Ph. Eur., Dronabinol, cannabis extracts and distillates, GMP documentation and supply planning for 2027.

Schlattingen, Switzerland – CPHI Milan opens on 6 October 2026 at Fiera Milano, and Canexis Pharma AG will be at stand 2D98 in the Natural Extracts zone for all three days. After expopharm in Munich in September, it is the second industry meeting this autumn at which the Swiss manufacturer presents its EU-GMP portfolio of cannabis-based active pharmaceutical ingredients.

What can be discussed at the stand: current specifications and Certificates of Analysis for Cannabidiol Ph. Eur., Dronabinol (USP/DAC), THCA, THC- and CBD-dominant cannabis extracts and distillates, and the standardized cannabis extracts Type I and Type II; sample requests and the documentation needed for qualification, from technical and quality agreements and on-site audits to national regulatory documentation and DMF/ASMF support; and supply agreements and volume planning for 2027, in pack sizes from 100 g to 25 kg.

"Most of the conversations we have at CPHI start with a specification and end with a timeline," says Adriano Meier, Co-Founder of Canexis Pharma AG. "That is exactly what we are there for: to go through the numbers, agree what a first delivery looks like and put a date on it."

Meetings can be booked in advance with the "Book a meeting" button on this profile or directly in the CPHI Event Planner; requests by e-mail to [email protected] are equally welcome. Visitors without an appointment will find the team at the stand throughout the show. The new product flyer is attached to this article, and the full product catalogue with key specifications, pack sizes and regulatory status is available on request at www.canexis.com.

About Canexis Pharma AG
Founded in 2020, Canexis Pharma AG extracts, refines and purifies cannabinoids from GACP-grown cannabis into pharmaceutical-grade bulk APIs at its site in the Canton of Thurgau. The site holds EU-GMP Part I and Part II licences, a Swissmedic manufacturing licence and a Swiss narcotics licence; the validated process chain covers extraction, decarboxylation, two-stage short-path distillation and crystallisation. Canexis supplies partners in regulated markets across Europe, APAC, LATAM and Africa. www.canexis.com